Laurie Freire Boullosa

University of Antwerp — Belgium

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index412citations16works13.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(4), Cancer Immunotherapy and Biomarkers(3), Immunotherapy and Immune Responses(3), Nanoplatforms for cancer theranostics(3), Acute Lymphoblastic Leukemia research(3)

Publications16 total

Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
Journal of Experimental & Clinical Cancer Research·2024· 13 citedOpen Access
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
OncoImmunology·2023· 12 citedOpen Access
Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
Antioxidants·2023· 23 citedOpen Access
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
Pharmaceutics·2022· 11 citedOpen Access
Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
Cells·2021· 65 citedOpen Access
Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
Redox Biology·2021· 103 citedOpen Access
Endogenous antioxidants in the prognosis and treatment of lung cancer
Cancer·2021· 1 cited
Contributors
Cancer·2021
Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
Cancer Drug Resistance·2021· 10 citedOpen Access
Abstract 2962: Molecular mechanisms underlying the sensitizing effect of mutant p53 protein expression for Auranofin treatment of NSCLC and PDAC cells
Cancer Research·2020
Abstract 2414: Immunogenic properties of chemotherapeutic agents in the treatment of non-small cell lung cancer
Cancer Research·2020
Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
Cells·2020· 47 citedOpen Access
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
Cancer Immunology Immunotherapy·2020· 4 citedOpen Access
Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
Cancers·2019· 108 citedOpen Access
PO-408 New targets for the immunotherapy of adult B-cell acute lymphocytic leukaemia
ESMO Open·2018Open Access
Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia
Oncotarget·2017· 15 citedOpen Access

Frequent Co-authors

Evelien Smits(13), Filip Lardon(10), Christophe Deben(10), Jinthe Van Loenhout(9), Tal Flieswasser(6), Jorrit De Waele(5), Christophe Hermans(5), Jonas R.M. Van Audenaerde(4), Julie Jacobs(4), Marc Peeters(4), Céline Merlin(4), Ho Wa Lau(4), Patrick Pauwels(4), Elly Marcq(3), Abraham Lin(3), Astrid Van den Eynde(3), Ken Mills(3), Kim Orchard(3), Barbara‐ann Guinn(3), Annemie Bogaerts(2)